Compass moves psychedelic-derived therapy closer to FDA review
Compass Pathways’ six-month Phase 3 update moves COMP360 from an unconventional treatment thesis toward late-stage regulatory execution.
Biotech becomes much more consequential when an unconventional therapy reaches pivotal trials and regulatory submission.
What happened
Compass Pathways reported 26-week results from its second Phase 3 COMP006 trial of investigational COMP360 for treatment-resistant depression.
The trial included nearly 600 participants. The company says 39% of participants in the 25 mg arm achieved a clinically meaningful reduction at week six and maintained benefit on average through at least week 26.
A rolling FDA submission is underway, with final submission expected in Q4 2026. These are company-reported clinical results, not a regulatory approval.
Why it matters
The significance is the transition from scientific promise toward regulatory execution.
Many novel psychiatric treatments remain stuck in early studies. Compass is now generating pivotal-trial data and moving through an FDA submission process.
That raises the stakes around durability, safety, treatment protocols and real-world delivery.
The bigger picture
Psychedelic-derived drug development is entering a more mature phase.
The market will increasingly be judged by late-stage evidence and regulatory outcomes rather than broad excitement around the science. Compass is becoming one of the clearest tests of whether the field can translate into approved medicine.